10x Genomics, Inc. — Director's Dealing 2021

Sep 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-09-07

Reporting Person: Saxonov Serge (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-26	Class A Common Stock	G	360	$0.00	Disposed	4498	Indirect
2021-09-07	Class A Common Stock	M	5209	$5.04	Acquired	903677	Direct
2021-09-07	Class A Common Stock	M	9791	$11.48	Acquired	913468	Direct
2021-09-07	Class A Common Stock	S	700	$184.4942	Disposed	912768	Direct
2021-09-07	Class A Common Stock	S	1200	$185.5035	Disposed	911568	Direct
2021-09-07	Class A Common Stock	S	2702	$186.7371	Disposed	908866	Direct
2021-09-07	Class A Common Stock	S	2025	$187.4494	Disposed	906841	Direct
2021-09-07	Class A Common Stock	S	1414	$188.5079	Disposed	905427	Direct
2021-09-07	Class A Common Stock	S	2800	$189.8108	Disposed	902627	Direct
2021-09-07	Class A Common Stock	S	3759	$190.4398	Disposed	898868	Direct
2021-09-07	Class A Common Stock	S	400	$191.125	Disposed	898468	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-07	Stock Option (right to buy)	$5.04	M	5209	Disposed	2028-11-02	Class A Common Stock (5209)	Direct
2021-09-07	Stock Option (right to buy)	$11.48	M	9791	Disposed	2029-05-10	Class A Common Stock (9791)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A Common Stock	89960	Indirect

Footnotes

F1: As of June 4, 2021, 4,858 shares of Class A Common Stock were held by the Andromeda Trust, for which the Reporting Person and his spouse serve as trustees (the "Andromeda Trust"), and which shares were received upon transfer from the Reporting Person. Following the disposition by gift of 360 shares on August 26, 2021, the Andromeda Trust holds 4,498 shares of Class A Common Stock.

F2: The shares are held by the Andromeda Trust.

F3: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4: Reflects the transfer by the Reporting Person of 4,858 shares of Class A Common Stock to the Andromeda Trust, as referenced in footnote (1).

F5: This transaction was executed in multiple trades at prices ranging from $184.00 to $184.855. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F6: This transaction was executed in multiple trades at prices ranging from $185.015 to $185.98. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F7: This transaction was executed in multiple trades at prices ranging from $186.105 to $187.095. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F8: This transaction was executed in multiple trades at prices ranging from $187.11 to $188.075. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F9: This transaction was executed in multiple trades at prices ranging from $188.155 to $189.06. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F10: This transaction was executed in multiple trades at prices ranging from $189.20 to $190.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F11: This transaction was executed in multiple trades at prices ranging from $190.08 to $191.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F12: This transaction was executed in multiple trades at prices ranging from $191.09 to $191.16. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F13: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

F14: This option, originally for 250,000 shares, of which 181,052 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F15: This option, originally for 145,786 shares, of which 87,656 have been exercised, vested as to one forty-eighth of the shares on May 1, 2019, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.